LIVE WEBINAR: Tuesday, January 26, 2021, 5:00 PM – 6:00 PM Eastern Time

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Targeted Therapy for Lung Cancer

Join us on Tuesday, January 26th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Joel W Neal, MD, PhD
Associate Professor of Medicine, Division of Oncology
Stanford Cancer Institute, Stanford University
Palo Alto, California


Paul K Paik, MD
Associate Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Novartis.

Tuesday, January 26, 2021
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR, ALK or ROS1 Mutation

  • Design, eligibility criteria and primary and secondary endpoints of the Phase III ADAURA trial evaluating adjuvant osimertinib versus placebo for early-stage NSCLC with EGFR mutation after complete tumor resection
  • Clinical benefit observed with adjuvant osimertinib in the ADAURA trial; implications for biomarker testing and clinical care
  • Optimal first-line treatment for patients with metastatic NSCLC with EGFR tumor mutations, including those with CNS metastases
  • Management of NSCLC in patients who experience disease progression on first-line osimertinib; novel agents and combination strategies
  • FDA approval and current clinical role of erlotinib in combination with ramucirumab for patients with previously untreated metastatic NSCLC with EGFR mutations
  • Current treatment approaches for patients with NSCLC with EGFR exon 20 insertions; available data with and current role of commercially available EGFR tyrosine kinase inhibitors
  • Mechanism of action of amivantamab and of mobocertinib and efficacy and safety data leading to FDA breakthrough therapy designations for these agents in the treatment of metastatic NSCLC with an EGFR exon 20 insertion mutation
  • Optimal selection of first- and later-line therapy for patients with metastatic NSCLC and an ALK rearrangement
  • FDA approval of brigatinib for patients with NSCLC and an ALK rearrangement who have not received prior treatment with an ALK inhibitor; integration into treatment algorithms
  • Efficacy, safety and current clinical role of entrectinib for NSCLC with ROS1 rearrangement
  • Clinical trial evidence supporting the ongoing evaluation of other “next-generation” ROS1 inhibitors (eg, lorlatinib, ceritinib) for patients with NSCLC

MODULE 2: Targeted Therapeutic Options for Patients with NSCLC Harboring Other Mutations

  • Available safety and efficacy results from the LIBRETTO-001 trial of selpercatinib for patients with RET fusion-driven NSCLC, including those with previously untreated disease
  • Recent FDA approval of selpercatinib for patients with metastatic NSCLC with a RET fusion; optimal integration into clinical practice
  • Clinical activity and safety of pralsetinib in patients with advanced NSCLC and RET fusions in the Phase I/II ARROW study
  • FDA breakthrough therapy designation for pralsetinib and potential clinical role
  • Design, eligibility criteria and key findings from the Phase II GEOMETRY mono-1 trial assessing capmatinib in patients with NSCLC with MET exon 14 mutations
  • Recent FDA approval and current clinical role of capmatinib
  • Available safety and efficacy data with tepotinib in patients with NSCLC with MET exon 14 mutations
  • Key findings from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan for NSCLC with HER2 mutation
  • FDA breakthrough therapy designation for trastuzumab deruxtecan and potential nonresearch role for patients with NSCLC and HER2 mutations
  • Early safety and efficacy data with and ongoing evaluation of the novel KRAS G12C inhibitor AMG 510 for NSCLC with KRAS mutation
  • Available clinical trial data with and optimal use of entrectinib and larotrectinib for patients with NSCLC harboring NTRK gene fusions  

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider emerging research information and available guideline recommendations to individualize first- and later-line therapy for patients with non-small cell lung cancer (NSCLC) harboring various targetable genetic abnormalities.
  • Recognize the spectrum of oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how these alterations might predict response or lack thereof to EGFR-directed therapies.
  • Appreciate recently presented Phase III research supporting the efficacy of adjuvant osimertinib for patients with NSCLC with EGFR mutations after complete resection, and consider the potential effects of this information on clinical practice.
  • Understand the design and eligibility criteria for ongoing clinical trials evaluating novel therapeutic approaches for NSCLC with an EGFR exon 20 insertion mutation, and enroll or refer appropriate patients for study participation.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC.
  • Convey the clinical relevance of a positive ROS1 mutation test result to appropriate patients with NSCLC, and appreciate available clinical research with approved and investigational agents demonstrating efficacy in such cases.
  • Assess available research with approved and emerging RET inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive NSCLC harboring one of these abnormalities.
  • Evaluate available clinical trial findings supporting the FDA approval of capmatinib for patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping, and identify individuals who might benefit from treatment with this novel compound.
  • Recall other oncogenic pathways (eg, HER2, NTRK, KRAS) mediating the growth of tumors in unique patient subsets, and consider published and emerging data with commercially available and experimental agents exploiting these targets.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr NealAdvisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Lilly, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics. Dr PaikAdvisory Committee: Calithera Biosciences, EMD Serono Inc, Xencor; Consulting Agreements: Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline; Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Novartis.